- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06174181
Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration (TREDIA)
December 8, 2023 updated by: Direction Centrale du Service de Santé des Armées
Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50.
Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks apart usually depending on the treatment regimen and the patient's response.
The IVI procedure requires a double disinfection with periocular and conjunctival cutaneous povidone-iodine.
Antiseptic agents such as povidone iodine are a highly likely factor in the development of dry eye syndrome.
Clinical data have demonstrated the abrasive and toxic effects of their use on the ocular surface, especially with repeated exposure (Saedon H, Nosek J, Phillips J. Ocular surface effects of repeated application of povisoden-iodine in patients receiving frequent intravitreal injections.
Cutaneous and Ocular Toxicology.
2017;36(4):343-6.).
The IVIS study coordinated by Prof. Dot reported impaired ocular surface and quality of life immediately after IVI.
The authors suggest 3 levels of action to improve immediate tolerance: (i) improve the basal status of the ocular surface, (ii) reduce the contact time with povidone-iodine which could be toxic to the ocular surface and (iii) improve immediate post-IVI treatment.
(Verrecchia S et al.
A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study.
Acta Ophthalmol.
2021 Mar 18).
This study is part of the extension of the IVIS study.
IVIs are effective and do not currently present a therapeutic alternative.
However, their role in the development or exacerbation of dry eye is still poorly evaluated although millions of IVIs are performed each year worldwide (1.3 million in France in 2019).
In addition, discomfort after injection is one of the factors that limit adherence to long-term IVI treatment, some patients fearing this repeated act.
We propose in this bicentric, prospective, randomized, parallel group study, to evaluate in this context the impact of the continuous consideration of the risk of dry eye.
The expected results are the objective improvement of dry eye indicators, comfort and quality of life of patients, all aimed at optimizing the adherence of our patients to their AMD treatment.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Corinne DOT, Pr.
- Phone Number: +33 472 366 099
- Email: corinne.dot@intradef.gouv.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Not yet recruiting
- Hôpital Avicenne
-
Contact:
- Audrey GIOCANTI-AUREGAN, Pr
- Phone Number: +33 148 955 218
- Email: audrey.giocanti@aphp.fr
-
Lyon, France, 69003
- Recruiting
- HIA Desgenettes
-
Contact:
- Corinne DOT, Pr.
- Phone Number: +33 472 366 099
- Email: corinne.dot@intradef.gouv.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult patient treated for exudative AMD with at least one eye receiving IVI with an anti-VEGF for at least 12 months.
- Patient with at least one untreated dry eye symptom.
- Only one eye is included per patient. For patients injected bilaterally, the eye with the lowest TBUT will be included, otherwise the one with the highest Oxford score, otherwise the one with the lowest Schirmer score. If these 3 parameters are similar, the right eye will be included by default.
- Patient who has given informed consent to participate and understands the information related to the study.
- Patient affiliated with a social security plan or beneficiary of such a plan.
- Concurrent participation in non-interventional research is allowed. Concurrent participation in interventional research may be evaluated on a case-by-case basis by the Principal Investigator.
Exclusion Criteria:
- Patients with meatus plugs at inclusion.
- Eye surgery ≤ 3 months pre-inclusion (including laser or refractive).
- Anticholinergic* treatment prior to inclusion.
- Patients unable to maintain follow-up during the study period.
- Evidence of active ocular infection in either eye.
- History or presence of non-drying ocular surface disorders in either eye.
- Trauma or surgery to the eyelids.
- Any ocular or systemic pathology or treatment identified by the Investigator as likely to interfere with the results of the study.
- Hypersensitivity to any component of the medical device.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Preservative-free ophtalmic lubricant emulsion countinuous during 6 month after intravitreal Injections for Age-related macular degeneration
|
Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
|
Other: Routine treatment
Preservative-free ophtalmic lubricant emulsion during few days after intravitreal Injections for Age-related macular degeneration
|
Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean tear break-up time (TBUT) at the end of the study
Time Frame: 24 weeks
|
Mean tear break-up time (TBUT) in seconds at the last study assessment.
This is the standard measurement performed in routine care, which reduces the probability of missing data
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ocular surface alteration after 24 weeks
Time Frame: 24 weeks
|
Ocular Staining Score d'Oxford
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 9, 2023
Primary Completion (Estimated)
October 9, 2024
Study Completion (Estimated)
October 9, 2025
Study Registration Dates
First Submitted
December 8, 2023
First Submitted That Met QC Criteria
December 8, 2023
First Posted (Actual)
December 18, 2023
Study Record Updates
Last Update Posted (Actual)
December 18, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022PPRC11
- 2023-A00620-45 (Registry Identifier: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Notal Vision Inc.CompletedNeovascular Age-related Macular Degeneration | Intermediate Age Related Macular Degeneration (Disorder)United States
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
Clinical Trials on Preservative-free ophtalmic lubricant emulsion
-
Ifocus OyeklinikkThe Research Council of NorwayRecruiting
-
University of IowaCompletedEye Pain | Ocular Surface Disease | Cystoid Macular Edema | Central Retinal Vein Occlusion With Macular Edema | Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis) | Exudative Age-Related Macular Degeneration, Unspecified Eye | Dry Eye SensationUnited States
-
Tufts Medical CenterRecruitingDry EyeUnited States
-
AllerganCompletedDry Eye SyndromesUnited States
-
Alcon ResearchCompleted
-
Association for Innovation and Biomedical Research...European Vision Institute Clinical Research NetworkCompletedOcular Hypertension | GlaucomaUnited Kingdom, Switzerland, Belgium, Italy, Portugal, Austria
-
University of FloridaCompletedDry Eye SyndromesUnited States
-
Chang Gung Memorial HospitalCompletedCataract | Dry Eye DiseaseTaiwan
-
AllerganCompletedDry Eye DiseaseFrance, Spain, Russian Federation, Belgium, Germany, Italy, United Kingdom, Australia
-
Chang Gung Memorial HospitalUnknown